Trinity Biotech PLC
TRIB- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000888721
No open-market purchases or sales by Trinity Biotech PLC insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $379.5K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Trinity Biotech PLC changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 20 | 20 | 0 |
| Shares | 6.32M | 6.20M | −118.9K (−1.9%) |
| Value | $5.96M | $5.93M | −$33.4K (−0.6%) |
New holders (4)
Institutions that held Trinity Biotech PLC at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cambridge Investment Research Advisors, Inc. | 111,400 | $106.0K | 0.00% |
| Dynamic Advisor Solutions LLC | 10,000 | $9.51K | 0.00% |
| Rhumbline Advisers | 1,860 | $1.79K | 0.00% |
| CGC Financial Services, LLC | 1,500 | $1.43K | 0.00% |
Sold out (4)
Institutions that held Trinity Biotech PLC at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Envestnet Asset Management Inc | 53,099 | $56.5K |
| Atria Wealth Solutions, Inc. | 34,300 | $32.2K |
| Susquehanna International Group, LLP | 14,684 | $13.8K |
| UBS Group AG | 12,092 | $11.4K |